期刊文献+

rBCG-HPV16L1-E7疫苗的构建和免疫原性研究

Construction of rBCG-HPV16L1-E7 and Study on Its Immunogenicity
下载PDF
导出
摘要 [目的]构建以BCG为载体的rBCG-HPV16L1-E7疫苗,研究rBCG-HPV16L1-E7重组表达体嵌合乳头状瘤病毒样颗粒(VLPs)对小鼠免疫功能的影响,初步评价此疫苗对HPV相关肿瘤(宫颈癌)的预防作用。[方法]电穿孔法将pIJ702-HPV16L1-E7分泌型穿梭表达质粒导入BCG中表达,构成rBCG-HPV16L1-E7疫苗。Western blot检测E7蛋白的表达。采用rBCG-HPV16L1-E7疫苗皮下注射于C57BL/6小鼠,51Cr释放法体外分析免疫鼠的细胞毒性T淋巴细胞活性(cytotoxic T lymphocyte,CTL),ELISA法检测免疫鼠血清中E7特异性抗体和细胞因子的表达水平。[结果]Western blot法分析证实,该重组疫苗能特异地表达HPV16 E7蛋白。以rBCG-HPV16L1-E7免疫小鼠后,检测到的细胞因子IL-2、IFNγ及E7抗体的含量明显升高,诱导机体产生特异的抗体反应以及CTL反应。[结论]rBCG-HPV16L1-E7能增强小鼠的细胞和体液免疫反应,可作为HPV16预防性疫苗。 [Objective]To construct a vaccine, rBCC-HPV16L1-E7 for HPV, and detect the specific CTI. effect of CD8^+ T lymphocyte generated by the virus-like particles(VLPs) and evaluate the potency of it. [ Methods] BCG were transfected with the recombinant by electroporation assay. The transient expression of HPV16L1-E7 in the transfected BCG was assayed by western blotting, rBCG-HPV16 L1-E7 were vaccinated to mice, and spleen cells were isolated. The activities of cytotoxic T lymphocytes (CTL) isolated from immunized mice were tested in vitro with ^51Cr specific release assay. Cytokines and antibodies were detected by ELISA method. [Results]Western blotting verified that E7 gene could be expressed in BCG. Secretions of cytokines IL-2,IFNγ and antibodies increased by injection of rBCG-HPV16L1-E7 vaccinations. The CTLs and E7 specific antibody from immunized mice were efficaciously activated by rBCG-HPV16L1-E7 plasmid. [Conclusion] Cell and humoral immune reaction of mice could be strengthened by rBCG-HPV16L1-E7 vaccine.
出处 《预防医学论坛》 2006年第3期257-262,共6页 Preventive Medicine Tribune
基金 山东省科技攻关计划项目资助(NO.022100119)
关键词 人乳头状瘤病毒16型 疫苗 E7基因 L1基因 重组 BCG 电穿孔 病毒样颗粒 HPV16 Vaccine E7 gene L1 gene Recombination Recombination BCG Electroporation Virus-like particles
  • 相关文献

参考文献22

  • 1Shi W,Bu P,Liu J,et al.Human papillomavirus type 16 E7 DNA vaccine:mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity[J].J Virol,1999,73(9):7 877-7 881.
  • 2Crawford L,Tommasino M.Oncogenes and antioncogenes in the development of HPV associated tumors[J].Clin Dermatol,1997,15(2):207-215.
  • 3Yamauchi F,Kato K,Iwata H.Spatially and temporally controlled gene transfer by electroporation into adherent cells on plasmid DNA-loaded electrodes[J].Nucleic Acids Res,2004,32(22):e187.
  • 4Nabeshima S,Murata M,Kashiwagi K,et al.Serum antibody response to tuberculosis-associated glycolipid antigen after BCG vaccination in adults[J].J Infect Chemother,2005,11 (5):256-258.
  • 5Ami Y,Izumi Y,Matsuo K,et al.Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity[J].J Virol,2005,79 (20):12 871-12 879.
  • 6Christopherson KW 2nd,Campbell J J,Hromas RA.Transgenic overexpression of the CC chemokine CCL21 disrupts T-cell migration[J].Blood,2001,98(13):3 562-3 568.
  • 7Narechania A,Chen Z,DeSalle R,et al.Phylogenetic incongruence among oncogenic genital alpha human papillomaviruses.J Virol,2005,79(24):15 503-15 510.
  • 8Chen LP,Thomas EK,Hu SL,et al.Human papillomavirus type16 nucleoprotein E7 is a tumor rejection antigen[J].Proc Natl Acad Sci U S A,1991,88(1):110-114.
  • 9Barbosa MS,Vass WC,Lowy DR,et al.In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential[J].J Virol,1991,65 (1):292-298.
  • 10Baud D,Ponci F,Bobst M,et al.Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1[J].J Virol,2004,78(23):12 901-12 909.

二级参考文献16

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部